Table 7.

Effects of EBNE on CD3⁺/CD19⁺ lymphocytes among PP cells

Group	CD3+ (%)	CD19+ (%)
Control	29.03±1.23	53.90±3.63
Model	56.06±5.60**	28.81±4.08**
EBNL + model	44.15±5.56**,##	42.80±5.87**,##
EBNM + model	35.73±4.47**,##	47.41±6.39**,##
EBNH + model	39.59±4.96**,##	41.31±5.66**,##

Notes: After cell counting, 10⁶ cells were placed in flow cytometry tubes for staining of cells. Single-cell suspensions prepared as described earlier were incubated with 1 μg of either anti-CD3 or anti-CD19 antibody for 30 minutes at 37°C in darkness. The cells were then pelleted, and the supernatant was decanted, after which the cells were washed in PBS twice and resuspended in 1.2 mL plastic tubes containing 500 μL PBS. Data were acquired on a BD FACSCalibur flow cytometer and analyzed with FlowJo Version 7.6.5 analysis software. The data are the mean ± SD (n=6/treatment).

^**Significant difference compared with the control group (P<0.01).

^##Significant difference compared with the CY group (P<0.01).

Abbreviations: EBNL, EBN low dose; EBNM, EBN medium dose; EBNH, EBN high dose; PP, Peyer’s patch; PBS, phosphate buffered saline; EBN, Edible bird’s nest; EBNE, EBN extract; CY, cyclophosphamide.